JAFL
ARQT icon

Jay A. Fishman Ltd’s Arcutis Biotherapeutics ARQT Stock Holding History

Jay A. Fishman Ltd’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
595,005
+28,275
+5% +$659K 1.24% 22
2026
Q1 		$13.4M Buy
566,730
+2,080
+0.4% +$53.1K 1.19% 22
2025
Q4 		$16.4M Sell
564,650
-1,000
-0.2% -$25.6K 1.35% 20
2025
Q3 		$10.7M Buy
565,650
+9,500
+2% +$150K 0.91% 25
2025
Q2 		$7.8M Buy
556,150
+23,000
+4% +$322K 0.75% 25
2025
Q1 		$8.34M Sell
533,150
-3,250
-0.6% -$45.8K 0.91% 20
2024
Q4 		$7.47M Buy
536,400
+118,400
+28% +$1.3M 0.7% 22
2024
Q3 		$3.89M Buy
418,000
+71,400
+21% +$705K 0.39% 31
2024
Q2 		$3.22M Buy
346,600
+122,300
+55% +$1.11M 0.34% 31
2024
Q1 		$2.22M Buy
224,300
+171,300
+323% +$1.28M 0.25% 35
2023
Q4 		$171K Sell
53,000
-34,000
-39% -$92.4K 0.02% 89
2023
Q3 		$462K Buy
87,000
+10,000
+13% +$85K 0.06% 66
2023
Q2 		$734K Buy
77,000
+13,200
+21% +$147K 0.09% 56
2023
Q1 		$702K Buy
63,800
+20,000
+46% +$289K 0.09% 55
2022
Q4 		$648K Sell
43,800
-3,000
-6% -$52.4K 0.09% 58
2022
Q3 		$894K Buy
46,800
+25,800
+123% +$585K 0.13% 50
2022
Q2 		$448K Buy
+21,000
New +$431K 0.06% 68

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jay A. Fishman Ltd's ARQT Position: Q2 2026 in Review

Jay A. Fishman Ltd increased its Arcutis Biotherapeutics (ARQT) stake by 5% in Q2 2026, buying an estimated $659K and bringing the position to 595,005 shares worth $15.6M. The position accounts for 1.24% of the portfolio, ranked #22.

Jay A. Fishman Ltd first reported a position in ARQT in Q2 2022 and has held it in 17 quarters since. The position peaked at $16.4M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jay A. Fishman Ltd held 595,005 shares of Arcutis Biotherapeutics worth $15.6M as of Q2 2026.
  • Jay A. Fishman Ltd bought 28,275 Arcutis Biotherapeutics shares in Q2 2026, an estimated $659K.
  • Arcutis Biotherapeutics made up 1.24% of Jay A. Fishman Ltd's portfolio in Q2 2026, its #22 holding.
  • Jay A. Fishman Ltd first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
  • Jay A. Fishman Ltd's Arcutis Biotherapeutics position peaked at $16.4M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jay A. Fishman Ltd's 13F filing for Q2 2026, filed 29 Jul 2026.